MC2 Therapeutics Announces Positive Top-line Results from Phase 3 Clinical Trial Comparing MC2-01 Cream to Taclonex® in Adults with Psoriasis
MC2 Therapeutics A/S, an emerging pharmaceutical company developing next generation patient-friendly topical therapies for skin and eye diseases, today announced the following top-line data from its US Phase 3 study (n=796) on the company’s investigational drug, MC2-01 Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%):
- MC2-01 Cream is superior to Taclonex® Topical Suspension (“Taclonex®”) at Week 8 based on treatment success defined as a minimum two-point decrease in the Physician Global Assessment (PGA) score (40.1% versus 24.0%, p < 0.0001). Accordingly, the trial met its primary endpoint to demonstrate non-inferiority of MC2-01 Cream to Taclonex®.
- MC2-01 Cream is superior to Taclonex® based on percentage reduction in mPASI from baseline to Week 8 (64.8% versus 52.3%, p < 0.0001) (MC2-01 Cream demonstrated fast onset of action with superiority (p < 0.009) to Taclonex® already at Week 1).
- MC2-01 Cream is superior to Taclonex® in Patient Treatment Convenience (p < 0.0001)
- MC2-01 Cream provides a robust reduction in itch (60.2% at Week 4) measured by the frequency of a four-grade or greater improvement on an 11-point numeric rating scale of itch severity.
“The significant improvements in both treatment success and patient reported treatment convenience are particularly encouraging,” said Linda Stein Gold, MD, Director of Dermatology Clinical Research at Henry Ford Health System in Detroit, Michigan, and lead investigator in the study. “Enhanced patient satisfaction enabled by the MC2-01 Cream PAD™ formulation may increase treatment compliance among patients, and positively impact real-life treatment outcomes even further. As such PAD™ Technology holds the promise of redefining topicals.”
The adverse events seen in the trial were predictable pharmacological class effects typically associated with calcipotriene and topical corticosteroids, and the safety profile of MC2-01 cream was similar to that known from Taclonex®.
MC2 Therapeutics is pursuing a patient-centric approach to treating psoriasis by developing a once-daily, non-greasy topical treatment that can be conveniently applied to a large surface area of the body and absorbs quickly into the skin to provide rapid symptom relief. MC2-01 Cream is designed to allow patients to comfortably wear clothes immediately after application and go about their daily routines.
“We are extremely pleased with these superiority data from the head-to-head study of MC2-01 Cream versus Taclonex®, which is widely regarded as a first line topical treatment of psoriasis,” stated Jesper J. Lange, President of MC2 Therapeutics. “Psoriasis is a life-long condition that significantly impacts patients’
quality of life. MC2-01 Cream is designed to provide patients a new standard of care for the topical treatment of psoriasis that helps them effectively and conveniently manage their condition and minimize disruption to their daily routine and social interactions.”
Lange added, “These data confirm the tremendous potential for PAD™ Technology as a broad platform for the development of new topical drugs that releases the full potential of the active ingredients, while being very pleasant to use for patients in daily routines. PAD™ Technology enables an expanded formulation space that opens the door for an array of new topical therapies that might not otherwise be developed e.g. due to challenges with delivery, solubility and stability of active ingredients.”
About the MC2-01 Phase 3 Trial
This Phase 3, randomized, multicenter, investigator-blind, parallel-group trial evaluated the efficacy and safety of MC2-01 Cream compared to MC2-01 vehicle and the active comparator (Taclonex®) in subjects with psoriasis vulgaris. The trial enrolled 796 patients at 55 dermatologists across the United States. Subjects applied trial medication topically once daily for eight weeks.
The primary objective was to show therapeutic non-inferiority of MC2-01 Cream to the active comparator, as well as to characterize the safety profile of MC2-01 Cream in subjects with psoriasis vulgaris. The primary efficacy endpoint was the proportion of subjects in each treatment group with “treatment success” at week eight, defined as a minimum two-point decrease from baseline in PGA score (i.e., a score of 0 (clear) or 1 (almost clear) disease for subjects with moderate disease at baseline, or a score of 0 (absent) for subjects with mild disease at baseline).
The full data from the trial will be presented at upcoming medical conferences. Global development of MC2- 01 will continue and MC2 Therapeutics plans to submit a New Drug Application (NDA) to FDA in the first half of 2019.
About MC2 Therapeutics A/S
MC2 Therapeutics A/S is a privately held pharmaceutical company that is applying its proprietary PAD™ Technology as a broad platform to enable the development of a new generation of patient friendly topical prescriptions and consumer healthcare products. The Company is advancing its own portfolio of products to treat skin and eye conditions and is collaborating with other pharmaceutical companies to unlock the full potential of their active pharmaceutical ingredients in new topical drug candidates.
For additional information on MC2 Therapeutics Group, please visit www.mc2therapeutics.com
MC2 Therapeutics A/S
Jesper J. Lange, +45 2018 2222
Mette Thorn Sorensen, +45 4138 4300
James Heins, +1 203-682-8512
Darcie Robinson, +1 203-682-8379
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Hilton Launches New Brand, Signia Hilton, Delivering Sophisticated Travel While Reimagining Meetings and Events22.2.2019 17:00:00 | Pressemelding
Hilton (NYSE: HLT) today announced the launch of Signia Hilton, its dynamic, new meetings-and-events-focused brand. The portfolio of hotels is setting out to transform the industry for meeting professionals and sophisticated business travelers by infusing state-of-the-art technology and design into every aspect of the guest experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005071/en/ The brand further reinforces Hilton’s commitment to innovation that meets the evolving needs of today’s travelers and will bring premium experiences to top urban and resort destinations around the world. “In our 100th year of hospitality, we are more focused than ever on providing exceptional experiences to all of our guests – and that includes evolving those experiences to meet their changing needs,” said Christopher J. Nassetta, president and CEO, Hilton. “We are proud to launch Signia Hilton, which exemplifies our innovative sp
Axonics® Granted Expanded CE Mark Label; First and Only Sacral Neuromodulation System Approved for Use with Full-Body MRI Scans22.2.2019 16:30:00 | Pressemelding
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, announced today that it has received CE mark approval for 1.5T and 3T full-body magnetic resonance imaging (“MRI”) conditional labeling for the Axonics r-SNM® System. The Axonics r-SNM System is the only implantable SNM system that has received full-body MRI conditional labeling for sale in Europe1. Raymond W. Cohen, Chief Executive Officer of Axonics, said, “Without this labeling, any patient requiring an MRI scan on any body part below the head must have their neurostimulator surgically explanted prior to the MRI scan, resulting in an additional surgery for the patient and additional costs to patients and the healthcare system. This authorization of full-body MRI scans in Europe is another important milestone for Axonics, differentiating our te
Fantastec Joins Forces with Arsenal FC Launching Official Blockchain Collectibles App22.2.2019 14:30:00 | Pressemelding
Fantastec announced today its first football licensing agreement with Premier League club Arsenal FC for a new blockchain authenticated collectibles app called Fantastec SWAP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005277/en/ Arsenal players appear on Fantastec SWAP in official licensing deal (Graphic: Business Wire) London-based Fantastec is a leading sports fan technology innovator, and its blockchain based ‘SWAP’ app will have broad appeal to global sports fans, gamers and sports card collectors alike. Fantastec SWAP unlocks unique and authentic club content through the app, like player autographs and exclusive footage. With its innovative blockchain technology, fans around the world can now discover, collect and swap officially licensed club collectibles with other fans with complete trust. “Fantastec SWAP is a game-changer for international football fans as well the sports collectibles industry,” commented
Volkswagen Protects Virtual Key Sharing App with Trustonic Application Protection22.2.2019 13:42:00 | Pressemelding
Volkswagen is working with mobile cyber security leader Trustonic to enable customers to use smartphones to access their vehicles, and to securely share their digital car keys to grant access to others via a smartphone app. Volkswagen is using the Trustonic Application Protection (TAP) platform to secure the mobile app and ensure that sensitive information and key transfer requests are securely displayed to, and approved by, a real authenticated user on a trusted device and not by hackers or malware simulating a user or device. “The smartphone is becoming the vehicle key of the future and our We Connect service is the interface for this today in the new Volkswagen Passat,” comments Alf Pollex, Head of Infotainment and Connected Car at Volkswagen AG. “The user installs the We Connect app on their smartphone which is then authorized via the infotainment system with a Transaction Number. The Mobile Key will be compatible with Android-based Samsung devices. No mobile network connection is
Mundipharma EDO GmbH: US FDA grants Orphan Drug Designation for etoposide toniribate in relapsed/refractory biliary tract cancer22.2.2019 13:30:00 | Pressemelding
Mundipharma EDO GmbH, part of the Mundipharma network of independent associated companies, and Imbrium Therapeutics L.P., an operating subsidiary of Purdue Pharma L.P., today announced that the US FDA has granted Orphan Drug Designation (ODD) to etoposide toniribate for the treatment of relapsed/refractory biliary tract cancer, also known as cholangiocarcinoma.3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005126/en/ Biliary tract cancer is a rare tumour with approximately 8,000 patients diagnosed in the US every year and 10,571 in Europe.4,5 The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US. Radical surgery is the only curative treatment for biliary tract cancer but, in most cases, the cancer is inoperable. Patients who fail first-line chemotherapy have limited treatment options and the standard of
Lenovo Data Center Group Delivers Broad Edge Computing Portfolio, Expands Investments in IoT22.2.2019 13:13:00 | Pressemelding
Next week at MWC Barcelona, Lenovo Data Center Group (DCG) will showcase continued investments in its solutions supporting IoT and edge computing as part of its IoT growth plan over the next few years. Building on the momentum of its fifth consecutive quarter of profit growth, Lenovo DCG is building a portfolio that takes infrastructure to where the data is, whether that be in the traditional data center, in the cloud or increasingly, at the edge. Today, around 10 percent of enterprise-generated data is created and processed outside a traditional centralized data center or cloud. By 2022, Gartner predicts this figure will reach 75 percent. This migration is driving increased concerns around data privacy, security and regulations coupled with challenges of latency, bandwidth and downtime. Lenovo is addressing these challenges by creating a broad portfolio of edge computing offerings that address the different ways that customers want to deploy edge computing solutions for IoT use cases.